Locally advanced or metastatic solid malignancy; exhausted all available therapy; has not received prior therapy with an anti-PD-1 or anti-PD-L1, anti-CTLA-4, OX-40, CD137; platinum-refractory/resistant ovarian cancer. Here, TNFRSF4 is linked to ovarian cancer.